Interdisziplinäre Therapieempfehlungen zur Behandlung des metastasierten Nierenzellkarzinoms

Zusammenfassung

In den letzten Monaten wurden vielversprechende Daten von neuen zielgerichteten Substanzen bei der Behandlung des metastasierten Nierenzellkarzinoms veröffentlicht. Mit der Zulassung der Tyrosinkinase-Inhibitoren Sunitinib und Sorafenib stehen zwei dieser neuen Substanzen nun auch im klinischen Alltag zur Verfügung. Hieraus ergeben sich für den Kliniker neue Möglichkeiten, aber auch Fragen, die im Folgenden von einem interdisziplinären Board diskutiert und anhand der aktuellen Datenlage beantwortet werden.

Abstract

Recently, new data have been published on the treatment of metastasized renal cell cancer using targeted therapies. With the approval of the tyrosine kinase inhibitors Sunitinib and Sorafenib, two of these new therapies are now available in clinical practice. This has raised both new opportunities and new questions for the health care professionals involved. Here we report on a consensus conference addressing these questions with answers based on evidence from the recent literature.

Schlüsselwörter

Nierenzellkarzinom - Metastasen - zielgerichtete Therapie - Immuntherapie

Key words

renal cell cancer - metastases - targeted therapy - immunotherapy

Literatur

• 1 Coppin C, Porzsolt F, Awa A. et al . Immunotherapy for advanced renal cell cancer.  Cochrane Database Syst Rev. 2005;  (1) CD001425
• 2 Flanigan R C, Salmon S E, Blumenstein B A. et al . Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.  N Engl J Med. Dec 6 2001;  345 (23) 1655-1659
• 3 Mickisch G H, Garin A, Poppel H van. et al . Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.  Lancet. Sep 22 2001;  358 (9286) 966-970
• 4 McDermott D F, Regan M M, Clark J I. et al . Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.  J Clin Oncol. Jan 1 2005;  23 (1) 133-141
• 5 Yang J C, Sherry R M, Steinberg S M. et al . Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.  J Clin Oncol. Aug 15 2003;  21 (16) 3127-3132
• 6 Gnarra J R, Tory K, Weng Y. et al . Mutations of the VHL tumour suppressor gene in renal carcinoma.  Nat Genet. May 1994;  7 (1) 85-90
• 7 Motzer R J, Hutson T E, Tomczak P. et al . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.  N Engl J Med. Jan 11 2007;  356 (2) 115-124
• 8 Motzer R J, Bacik J, Murphy B A. et al . Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.  J Clin Oncol. Jan 1 2002;  20 (1) 289-296
• 9 Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, O'Toole T, Park Y, Moore L. LBA4: A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC).  Am Soc Clin Oncol Proc. 2006;  24 (18 s Part II) 930s
• 10 Escudier B, Eisen T, Stadler W M. et al . Sorafenib in advanced clear-cell renal-cell carcinoma.  N Engl J Med. Jan 11 2007;  356 (2) 125-134
• 11 Motzer R J, Michaelson M D, Redman B G. et al . Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.  J Clin Oncol. Jan 1 2006;  24 (1) 16-24
• 12 Motzer R J, Rini B I, Bukowski R M. et al . Sunitinib in patients with metastatic renal cell carcinoma.  Jama. Jun 7 2006;  295 (21) 2516-2524
• 13 Ratain M J, Eisen T, Stadler W M. et al . Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.  J Clin Oncol. Jun 1 2006;  24 (16) 2505-2512
• 14 Yang J C, Haworth L, Sherry R M. et al . A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.  N Engl J Med. Jul 31 2003;  349 (5) 427-434
• 15 Negrier S, Escudier B, Lasset C. et al . Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie.  N Engl J Med. Apr 30 1998;  338 (18) 1272-1278
• 16 Atzpodien J, Kirchner H, Jonas U. et al . Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).  J Clin Oncol. Apr 1 2004;  22 (7) 1188-1194
• 17 Pyrhonen S, Salminen E, Ruutu M. et al . Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer.  J Clin Oncol. Sep 1999;  17 (9) 2859-2867
• 18 Atzpodien J, Schmitt E, Gertenbach U. et al . Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).  Br J Cancer. Mar 14 2005;  92 (5) 843-846